Natural Killer-cell Therapy for Acute Myeloid Leukemia

Inclusion Criteria: * AML patients (de novo and secondary) or patients with MDS excess blasts-2 according to WHO criteria 2016, who have stable disease or non-rapidly progressive disease with or without disease controlling medication who are (at time of inclusion) ineligible for allo-SCT. * Patients may belong to any of the following categories: * Relapsed/refractory disease after treatment with intensive chemotherapy, hypomethylating agents, targeted agents, autologous or allo-SCT (at least 6 months ago) and DLI * Newly diagnosed, untreated patients ineligible for allo-SCT Other inclusion criteria: * Age ≥ 18 years * WHO performance 0-2 * Life expectancy of \> 4 months * Written informed consent * Hydrea is allowed as pre-treatment to control blast count until day -3 * Other disease controlling medication is allowed until day -7 Exclusion Criteria: * Progressive disease according to ELN criteria in case of previous therapy * Patients on immunosuppressive drugs or active GvHD * Patients with active infections (viral, bacterial or fungal); acute anti-infectious therapy must have been completed within 14 days prior to study treatment * Severe cardiovascular disease (CTCAE III-IV) * Severe pulmonary dysfunction (CTCAE III-IV) * Severe renal dysfunction (CTCAE III-IV) * Severe hepatic dysfunction (CTCAE III-IV) * Severe neurological or psychiatric dysfunction (CTCAE III-IV) * Patients on concurrent chemotherapy or interferon-alpha treatment * Pregnancy or breastfeeding